FUJIFILM Cellular Dynamics FCDI Facebook FCDI Twitter FCDI LinkedIn FCDI Youtube
September 2021EventsPublications
FCDI
Events
Drug Target Review Webinar

WEBINAR: Cardiac Proarrhythmic Risk Assessment Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Oct  5, 2021 | 9:00 AM & 8:00 PM MDT

Join this Eurofins-sponsored webinar to learn about hiPSC-CM based assays on both MEA and calcium transient FLIPR platforms for comprehensive pre-clinical cardiac liability assessment.

See the Article

Safety Pharmacology Society
2021 Annual Meeting

Join FCDI at the virtual SPS 2021 meeting. Two poster presentations using iCell® Cardiomyocytes products will highlight new approaches to cardiotox.

See the Article
Safety Pharmoacology Society Annual Meeting 2021

Cell & Gene Meeting on the Mesa 2021

Cell & Gene Meeting on the Mesa

Oct  12-14, 2021 | Park Hyatt Aviara Resort, Carlsbad CA and Online

FCDI CEO Takeshi Yamamoto will present at Meeting on the Mesa on the state of FCDI technology, including CDMO services using its state-of-the-art clinical manufacturing facility, and applications in discovery and therapeutics research.

See the Article
Publications

A Multiscale Approach for Bridging the Gap Between Potency, Efficacy, and Safety of Small Molecules Directed at Membrane Proteins

Aguayo-Ortiz R, Creech J, Jiménez-Vázquez EN, Guerrero-Serna G, Wang N, da Rocha AM, Herron TJ, Espinoza-Fonseca LM. Sci Rep. 2021 Aug 16;11(1):16580. PMID: 34400719.

This research describes efforts to accelerate the translation of basic science discoveries into potential drug candidates targeting transmembrane protein domains by in silico modeling of ligand–membrane interactions with human iPSC-derived cardiomyocytes to gain insights into drug delivery, cellular efficacy, and safety of molecules directed at membrane proteins.

See the Article

Nature Scientific Reports

Cell Reports Medicine

Secreted Retrovirus-Like GAG-Domain-Containing Protein PEG10 is Regulated by UBE3A and is Involved in Angelman Syndrome Pathophysiology

Pandya NJ, Wang C, et al. Cell Rep Med. 2021 Aug 17;2(8):100360. PMID: 34467244.

See how this team used human iPSC-derived neuronal models including iCell GlutaNeurons to model Angelman Syndrome and investigate the pathophysiology of the disease in this elegant paper.

See the Article

Restoring Lost Nigrostriatal Fibers in Parkinson's Disease Based on Clinically-Inspired Design Criteria

Gordián-Vélez WJ, Chouhan D, España RA, Chen HI, Burdick JA, Duda JE, Cullen DK. Brain Res Bull. 2021 Oct;175:168-185. PMID: 34332016.

This research paper describes a tissue engineering-based fabrication of hydrogel-encased dopaminergic axon tracts, in vitro, using iCell DopaNeurons with the eventual therapeutic aim of nigrostriatal pathway restoration. See their progress in characterizing and optimizing the constructs in this innovative Parkinson's Disease research paper.

See the Article

Brain Research Bulletin

Nature Communications

Improved Modeling of Human AD with an Automated Culturing Platform for iPSC Neurons, Astrocytes and Microglia

Bassil R, Shields K, Granger K, Zein I, Ng S, Chih B. Nat Commun. 2021 Sep 1;12(1):5220. PMID: 34471104.

Read about how iCell Microglia were incorporated into an iPSC triculture system model of Alzheimer's Disease. The model system was used to demonstrate that microglia amyloid phagocytosis leads to plaque formation.

See the Article

Copyright © 2021 FUJIFILM Cellular Dynamics